ALX Oncology (ALXO) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed ALX Oncology (ALXO) over the past year, gaining 7.4% versus a loss of 40.1%. Over five years, MSLE leads with a -50.8% price change compared with -98.0% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $158.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | MSLE |
|---|---|---|
| Share price | $1.25 | $7.49 |
| Market cap | $172.85M | $158.91M |
| 1-day change | +5.93% | +1.97% |
| YTD return | +4.42% | +24.91% |
| 1-year return | -40.10% | +7.38% |
| 5-year return | -98.00% | -50.84% |
| EPS (TTM) | $-1.13 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $13.40 |
| 52-week low | $1.05 | $5.30 |
| Distance from 52-week high | -53.01% | -44.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +244.46% |
| Average volume | 1.04M | 50.10K |
| Shares outstanding | 138.28M | 21.22M |
| Employees | 48 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed ALXO by 47.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
ALXO vs MSLE FAQ
Which is bigger, ALX Oncology or Satellos Bioscience?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $158.91M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, ALXO or MSLE?
MSLE returned +7.38% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.